Coley Pharmaceuticals (COLY) is yet another small-cap biopharma one-trick pony that fell apart like a cheap clock. Pfizer (PFE) had been conducting trials of a lung cancer drug licensed from Coley, and a review committee says test have been ineffective.
Trials will be discontinued. Coley lost $35 million last year on revenue of $20 million, and the bottom line has been that way for three years.
It is a miracle of sorts that the company’s shares hit $13.90 late last year. They have not traded below $8 over the last 52-week period. But, today they fell to $2.99, which is the only part of the entire affair that makes any sense.
Douglas A. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
